Could a single injection reprogram immune cells to tame lupus and scleroderma?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 to 69 years, regardless of gender. * Adequate bone marrow, coagulation, cardiopulmonary, hepatic, and renal function. * Participants who are not pregnant or breastfeeding and who agree to use effective contraception for 12 months after drug infusion, if applicable. * Diagnosis of systemic lupus erythematosus (SLE) according to the 2019 EULAR/ACR classification criteria, with a history of SLE for at least 6 months; during screening, participants must have positive antinuclear antibody (ANA), and/or positive anti-double-stranded DNA antibody, and/or hypocomplementemia. * Diagnosis of systemic sclerosis (SSc) according to the 2013 ACR/EULAR classification criteria, including limited cutaneous or diffuse cutaneous systemic sclerosis, with new or progressive skin manifestations within 6 months before screening. Exclusion Criteria: * Positive hepatitis B surface antigen (HBsAg), or positive hepatitis B core antibody (HBcAb) with detectable or quantifiable HBV DNA; positive hepatitis C antibody with detectable or quantifiable HCV RNA; positive HIV antibody; positive CMV DNA; or positive syphilis antigen or antibody. * Presence of any other uncontrolled active infection. * History of major solid organ transplantation (for example, heart, lung, liver, or kidney transplantation) or bone marrow/hematopoietic stem cell transplantation. * Pregnant or breastfeeding women. * Receipt of any mRNA-LNP product or other LNP-based drug within the past 2 years. * History, within 6 months before screening, of any of the following cardiovascular conditions: NYHA Class III or IV heart failure, myocardial infarction, unstable angina, uncontrolled or symptomatic atrial arrhythmia, ventricular arrhythmia, or other clinically significant cardiac disease. * Receipt of a live vaccine within 30 days before screening. * History of asthma or severe allergy, if considered clinically significant by the investigator. * Any condition that, in the investigator's opinion, would increase risk to the participant or interfere with study assessments.